Cargando…

An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus

Detalles Bibliográficos
Autores principales:	Eisenberg, RA, Khan, S, Stansberry, J, Tsai, D, Kolasinski, S, Rieder, E, Kotzin, B, Looney, RJ, Strieber, C, Albert, D
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833537/ http://dx.doi.org/10.1186/ar1407

Ejemplares similares

A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
por: Eisenberg, R, et al.
Publicado: (2003)

Rituximab reduces anti-cardiolipin levels in patients with systemic lupus erythematosus
por: Martínez-Pérez, R, et al.
Publicado: (2010)

Off-label use of rituximab for systemic lupus erythematosus in Europe
por: Rydén-Aulin, Monica, et al.
Publicado: (2016)

Off-label use of rituximab in systemic lupus erythematosus: a systematic review
por: Murray, Eleanor, et al.
Publicado: (2010)

SLE - Rituximab in lupus
por: Eisenberg, Robert
Publicado: (2003)

Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus
por: Wincup, Chris, et al.
Publicado: (2019)

Rituxan-Induced Tumor Lysis Syndrome in a Patient With Diffuse Large B-Cell Lymphoma
por: Iftikhar, Saffa, et al.
Publicado: (2021)

Rituximab therapy for juvenile-onset systemic lupus erythematosus
por: Nwobi, Obioma, et al.
Publicado: (2007)

Rituximab reduces the hospitalization in patients with systemic lupus erythematosus
por: Martínez-Pérez, R, et al.
Publicado: (2010)

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
por: Hassan, Sabih Ul, et al.
Publicado: (2020)

First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis
por: Faustini, Francesca, et al.
Publicado: (2021)

Steroid-Resistant Autoimmune Thrombocytopenia in Systemic Lupus Erythematosus Treated with Rituximab
por: Sardesai, Vasudha V, et al.
Publicado: (2015)

Analysis of rituximab’s usage for the treatment of pediatric systemic lupus erythematosus
por: Alves, Alessandra, et al.
Publicado: (2014)

Thrombotic thrombocytopenic purpura treated with rituximab in systemic lupus erythematosus
por: Karimifar, Mansoor
Publicado: (2012)

Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus
por: Bonilla-Abadía, Fabio, et al.
Publicado: (2014)

Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus
por: Penha, Mariana Álvares, et al.
Publicado: (2018)

Anti-Cytokine Autoantibodies in Systemic Lupus Erythematosus
por: Howe, Hwee Siew, et al.
Publicado: (2019)

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy
por: Rapoport, AP, et al.
Publicado: (2002)

B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab
por: Wiesik-Szewczyk, E, et al.
Publicado: (2012)

Rituximab Therapy for Refractory Autoimmune Thrombocytopenia in Patients with Systemic Lupus Erythematosus
por: Atay, Didem, et al.
Publicado: (2012)

Use of rituximab as a treatment for systemic lupus erythematosus: retrospective review
por: Machado, Roberta Ismael Lacerda, et al.
Publicado: (2014)

Refractory Orbital Myositis in Systemic Lupus Erythematosus A Role for Rituximab
por: Rodrigues Morais, Joana, et al.
Publicado: (2021)

Anti-TNF-α Therapies in Systemic Lupus Erythematosus
por: Zhu, Lang-Jing, et al.
Publicado: (2010)

Anti-IL-10 antibody in systemic lupus erythematosus
por: Uchida, Marina, et al.
Publicado: (2019)

Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review
por: Sans-Pola, Carla, et al.
Publicado: (2023)

Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
por: Hennessey, Ashleigh, et al.
Publicado: (2019)

Efficacy and safety of rituximab for systemic lupus erythematosus treatment: a meta-analysis
por: Wu, Shanshan, et al.
Publicado: (2020)

Successful Treatment of Urticarial Vasculitis in a Patient With Systemic Lupus Erythematosus With Rituximab
por: Alharbi, Samar, et al.
Publicado: (2020)

The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
por: Abid, Naushad, et al.
Publicado: (2023)

Anti-Sm antibodies in the classification criteria of systemic lupus erythematosus
por: van Beers, Joyce J.B.C., et al.
Publicado: (2022)

An Emerging Role for Anti-DNA Antibodies in Systemic Lupus Erythematosus
por: Kubota, Tetsuo
Publicado: (2023)

Structural Characterization of the Full-Length Anti-CD20 Antibody Rituximab
por: Belviso, Benny Danilo, et al.
Publicado: (2022)

The impact of glucocorticoids and anti-cd20 therapy on cervical human papillomavirus infection risk in women with systemic lupus erythematosus
por: Mendoza-Pinto, Claudia, et al.
Publicado: (2013)

Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy
por: Tanaka, Yoshiya, et al.
Publicado: (2016)

Anti‐dsDNA, anti‐nucleosome, anti‐C1q, and anti‐histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity
por: Shang, Xiaoying, et al.
Publicado: (2021)

Internalization of Rituximab and the Efficiency of B Cell Depletion in Rheumatoid Arthritis and Systemic Lupus Erythematosus
por: Reddy, Venkat, et al.
Publicado: (2015)

Efficacy of Rituximab in a Systemic Lupus Erythematosus Patient Presenting with Diffuse Alveolar Hemorrhage
por: Montes-Rivera, Gabriela, et al.
Publicado: (2017)

Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to standard of care
por: Chessa, Elisabetta, et al.
Publicado: (2017)

Vesiculobullous disease with Cutaneous Systemic Lupus Erythematosus Treated by Rituximab: A case report
por: Mohammed Niamat Alla, Wigdan, et al.
Publicado: (2021)

Elevated titers of anti-ribosomal-P antibodies in systemic lupus erythematosus
por: Zandman-Goddard, G, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_ojt22o69ctopoc6bioued7rebe